However, these trials contained different chemotherapy backbones and as recently reported in oesophageal adenocarcinoma, the monoclonal antibody cetuximab may be less biologically active in this group that anti-EGFR tyrosine kinase inhibitors (Gold et al, 2010). Here, EGFR is linked to esophageal adenocarcinoma.